Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025)
Monopar Therapeutics (MNPR) posted Other Operating Expenses of -$1.0 for Q3 2025, down 100.0% sequentially from $14.5 million in Q3 2017.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025) Analysis & Trends
Monopar Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at -$1.0 in Q3 2025.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$1.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$1.0 (changed N/A YoY) and the FY2017 annual result came in at $14.5 million, changed N/A from the prior year.
- Other Operating Expenses slipped to -$1.0 in Q3 2025 per MNPR's latest filing, from $14.5 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$1.0 in Q3 2025 and troughed at -$1.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Monopar Therapeutics | 1.01 Bn | 957.41 Mn | - |